The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD.

Cero will use Invivoscribe's multiparametric flow cytometry assay to detect minimal residual disease in patients and evaluate the therapy's efficacy.

1 Introduction Acute myeloid leukemia (AML) is a prevalent malignant myeloid tumor, predominantly occurring in elderly patients. Allogeneic hematopoietic cell transplantation (allo-HCT) remains the ...

FluoroFinder's platform streamlines fluorescent experiment design with workflow solutions for flow cytometry and fluorescent microscopy. Combining AI with machine learning, our technology analyzes ...

Between 2008 and 2023, its oncology immunophenotyping lab saw the number of requests for flow cytometry increase from 3,000 to 8,500 per year, with samples of different types, which can add to the ...

The upcoming webinar will delve into the advanced applications of Next Generation Flow™ in the analysis of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Dr. Juan Flores-Montero, a ...

Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML AML patients with diverse mutations, including ...

Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML Addition of TUS to standard of care VEN+AZA creates ...

NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases, 1 stable over time, 2 and, if present in blood at allele fractions ≥0.01% ...

Addition of TUS to standard of care VEN+AZA creates a well-tolerated and mutation agnostic frontline triple drug therapy for newly diagnosed AML AML patients with diverse mutations, including TP53 ...